These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35482574)

  • 1. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022.
    Clarke KEN; Jones JM; Deng Y; Nycz E; Lee A; Iachan R; Gundlapalli AV; Hall AJ; MacNeil A
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(17):606-608. PubMed ID: 35482574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Social Vulnerability and SARS-CoV-2 Seroprevalence in Specimens Collected From Commercial Laboratories, United States, September 2021-February 2022.
    Benoit TJ; Kim Y; Deng Y; Li Z; Harding L; Wiegand R; Deng X; Jones JM; Ronaldo I; Clarke KEN
    Public Health Rep; 2024; 139(4):501-511. PubMed ID: 38357883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
    Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
    JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022.
    Wiegand RE; Deng Y; Deng X; Lee A; Meyer WA; Letovsky S; Charles MD; Gundlapalli AV; MacNeil A; Hall AJ; Thornburg NJ; Jones J; Iachan R; Clarke KEN
    Lancet Reg Health Am; 2023 Feb; 18():100403. PubMed ID: 36479424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants - United States, June 2021-January 2022.
    Lambrou AS; Shirk P; Steele MK; Paul P; Paden CR; Cadwell B; Reese HE; Aoki Y; Hassell N; Zheng XY; Talarico S; Chen JC; Oberste MS; Batra D; McMullan LK; Halpin AL; Galloway SE; MacCannell DR; Kondor R; Barnes J; MacNeil A; Silk BJ; Dugan VG; Scobie HM; Wentworth DE; Caravas J; Kovacs NA; Gerhart JG; Jia Ng H; Beck A; Chau R; Cintron R; Cook PW; Gulvik CA; Howard D; Jang Y; Knipe K; Lacek KA; Moser KA; Paskey AC; Rambo-Martin BL; Nagilla RR; Retchless AC; Schmerer MW; Seby S; Shepard SS; Stanton RA; Stark TJ; Uehara A; Unoarumhi Y; Bentz ML; Burgin A; Burroughs M; Davis ML; Keller MW; Keong LM; Le SS; Lee JS; Madden Jr JC; Nobles S; Owuor DC; Padilla J; Sheth M; Wilson MM; ;
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):206-211. PubMed ID: 35143464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network - 13 Academic Medical Centers, April-June 2020.
    Self WH; Tenforde MW; Stubblefield WB; Feldstein LR; Steingrub JS; Shapiro NI; Ginde AA; Prekker ME; Brown SM; Peltan ID; Gong MN; Aboodi MS; Khan A; Exline MC; Files DC; Gibbs KW; Lindsell CJ; Rice TW; Jones ID; Halasa N; Talbot HK; Grijalva CG; Casey JD; Hager DN; Qadir N; Henning DJ; Coughlin MM; Schiffer J; Semenova V; Li H; Thornburg NJ; Patel MM; ;
    MMWR Morb Mortal Wkly Rep; 2020 Sep; 69(35):1221-1226. PubMed ID: 32881855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.
    Hoballah A; El Haidari R; Siblany G; Abdel Sater F; Mansour S; Hassan H; Abou-Abbas L
    BMC Infect Dis; 2022 Jan; 22(1):42. PubMed ID: 35012464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Over Time in 10 Sites in the United States, March-August, 2020.
    Lim T; Delorey M; Bestul N; Johannson MA; Reed C; Hall AJ; Fry AM; Edens C; Semenova V; Li H; Browning P; Desai R; Epperson M; Jia T; Thornburg NJ; Schiffer J; Havers FP
    Clin Infect Dis; 2021 Nov; 73(10):1831-1839. PubMed ID: 33639620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.
    Bajema KL; Wiegand RE; Cuffe K; Patel SV; Iachan R; Lim T; Lee A; Moyse D; Havers FP; Harding L; Fry AM; Hall AJ; Martin K; Biel M; Deng Y; Meyer WA; Mathur M; Kyle T; Gundlapalli AV; Thornburg NJ; Petersen LR; Edens C
    JAMA Intern Med; 2021 Apr; 181(4):450-460. PubMed ID: 33231628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 SeroHub, an online repository of SARS-CoV-2 seroprevalence studies in the United States.
    Freedman ND; Brown L; Newman LM; Jones JM; Benoit TJ; Averhoff F; Bu X; Bayrak K; Lu A; Coffey B; Jackson L; Chanock SJ; Kerlavage AR
    Sci Data; 2022 Nov; 9(1):727. PubMed ID: 36435936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High SARS-CoV-2 Seroprevalence in Rural Peru, 2021: a Cross-Sectional Population-Based Study.
    Moreira-Soto A; Pachamora Diaz JM; González-Auza L; Merino Merino XJ; Schwalb A; Drosten C; Gotuzzo E; Talledo M; Arévalo Ramirez H; Peralta Delgado R; Bocanegra Vargas S; Drexler JF
    mSphere; 2021 Dec; 6(6):e0068521. PubMed ID: 34817236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.
    Barchuk A; Skougarevskiy D; Kouprianov A; Shirokov D; Dudkina O; Tursun-Zade R; Sergeeva M; Tychkova V; Komissarov A; Zheltukhina A; Lioznov D; Isaev A; Pomerantseva E; Zhikrivetskaya S; Sofronova Y; Blagodatskikh K; Titaev K; Barabanova L; Danilenko D
    PLoS One; 2022; 17(6):e0266945. PubMed ID: 35704649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Seroprevalence and Cross-Variant Antibody Neutralization in Cats, United Kingdom.
    Tyson GB; Jones S; Logan N; McDonald M; Marshall L; Murcia PR; Willett BJ; Weir W; Hosie MJ
    Emerg Infect Dis; 2023 Jun; 29(6):1223-1227. PubMed ID: 37141617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
    Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP;
    Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric Infection-Induced SARS-CoV-2 Seroprevalence Increases and Seroprevalence by Type of Clinical CareSeptember 2021 to February 2022.
    Clarke KEN; Kim Y; Jones J; Lee A; Deng Y; Nycz E; Iachan R; Gundlapalli AV; MacNeil A; Hall A
    J Infect Dis; 2023 Feb; 227(3):364-370. PubMed ID: 36281757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
    Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
    Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19).
    Kislaya I; Gonçalves P; Gómez V; Gaio V; Roquette R; Barreto M; Sousa-Uva M; Torres AR; Santos J; Matos R; Manita C; Almeida Santos J; Soeiro S; de Sousa R; Costa I; Verdasca N; Guiomar R; Rodrigues AP;
    Infect Dis (Lond); 2022 Jun; 54(6):418-424. PubMed ID: 35023439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: Active prospective surveillance, December 2020 to March 2021, England.
    Ladhani SN; Ireland G; Baawuah F; Beckmann J; Okike IO; Ahmad S; Garstang J; Brent AJ; Brent B; Aiano F; Amin-Chowdhury Z; Kall M; Borrow R; Linley E; Zambon M; Poh J; Warrener L; Lackenby A; Ellis J; Amirthalingam G; Brown KE; Ramsay ME
    J Infect; 2021 Nov; 83(5):573-580. PubMed ID: 34400220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.